SCHEMBL6046979

SCHEMBL6046979

COc1ccc(C(OC[C@H]2O[C@@H](n3ccc(NC(=O)COc4ccc(C(C)(C)C)cc4)nc3=O)C[C@@H]2O)(c2ccccc2)c2ccc(OC)cc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TYMP P19971 2/20 0.45
POLB P06746 3/20 0.43
NT5E P21589 2/20 0.42
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
LMNA P02545 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HCAR2 Q8TDS4 1/20 0.38
ABL1 P00519 1/20 0.38
RIN1 Q13671 1/20 0.38
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
ADRB2 P07550 1/20 0.37
HPGD P15428 1/20 0.37
P2RY6 Q15077 2/20 0.37
P2RY14 Q15391 2/20 0.37
TYMS P04818 1/20 0.37
DUT P33316 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24115327 0.90 TYMP (0.48) TYMPPOLBNT5EABL1RIN1
SCHEMBL20596260 0.90 TYMP (0.48) TYMPPOLBNT5EABL1RIN1
SCHEMBL31556085 0.90 TYMP (0.48) TYMPPOLBNT5EABL1RIN1
SCHEMBL31556049 0.90 TYMP (0.48) TYMPPOLBNT5EABL1RIN1
SCHEMBL9236653 0.89 TYMP (0.45) TYMPPOLBNT5ERAB9ASMN1; SMN2
SCHEMBL10491019 0.88 POLB (0.54) TYMPPOLBNT5EABL1RIN1
SCHEMBL5925303 0.88 POLB (0.56) TYMPPOLBNT5EABL1RIN1
SCHEMBL5358852 0.88 POLB (0.56) TYMPPOLBNT5EABL1RIN1
SCHEMBL30274954 0.88 TYMP (0.46) TYMPPOLBNT5ENPC1RAB9A
SCHEMBL27041182 0.88 TYMP (0.46) TYMPPOLBNT5ENPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060154256-A1 Method for covalently attaching nucleosides and/or nucleotides on surfaces and method for determining coupling yields in the synthesis of nucleotides CHEMOGENIX GMBH (DE) 2006-07-13 US disclosed
EP-1438322-A2 METHOD FOR COVALENTLY ATTACHING NUCLEOSIDES AND/OR NUCLEOTIDES ON SURFACES AND METHOD FOR DETERMINING COUPLING YIELDS IN THE SYNTHESIS OF NUCLEOTIDES Chemogenix GmbH (DE) 2004-07-21 EP disclosed
WO-2003035664-A2 METHOD FOR COVALENTLY ATTACHING NUCLEOSIDES AND/OR NUCLEOTIDES ON SURFACES AND METHOD FOR DETERMINING COUPLING YIELDS IN THE SYNTHESIS OF NUCLEOTIDES CHEMOGENIX GMBH (DE) 2003-05-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060154256-A1 Method for covalently attaching nucleosides and/or nucleotides on surfaces and method for determining coupling yields in the synthesis of nucleotides NUDT1, PNP, NME2 TYMP 13/4885POLB 220/4885NT5E 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.